Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial
ACET•FDA clears ADI-212 IND
FDA cleared Adicet Bio’s IND for ADI-212 in metastatic castration-resistant prostate cancer.
Phase 1 enrollment timing
Phase 1 enrollment is expected to start in Q4 2026.
